journal article Open Access Nov 12, 2020

The inflammation in cutaneous lichen planus is dominated by IFN‐ϒ and IL‐21—A basis for therapeutic JAK1 inhibition

Experimental Dermatology Vol. 30 No. 2 pp. 262-270 · Wiley
View at Publisher Save 10.1111/exd.14226
Abstract
AbstractCutaneous lichen planus (CLP) and psoriasis (PSO) are both common chronic inflammatory skin diseases for which development of new treatments requires the identification of key targets. While PSO is a typical Th17/IL‐17‐disorder, there is some evidence that Th1/IFN‐ɣ dominate the inflammatory process in CLP. Nonetheless, the immunopathogenesis of CLP is not fully explained and key immunological factors still have to be recognized. In this study, we compared the immune signature of CLP lesions with the well‐characterized inflammation present in PSO skin. First, we analysed the histological and immunohistological characteristics of CLP and PSO. Second, we assessed the cytokine expression (IL1A, IL1B, IL4, IL6, IL8, IL10, IL17A, IL19, IL21, IL22, IL23A, IL13, IFNG, TNF, IL12A, IL12B and IL36G) of lesional skin of CLP with PSO by qPCR. Histology revealed a similar epidermal thickness in CLP and PSO. Immunohistochemically, both diseases presented with an inflammatory infiltrate mainly composed by CD3+CD4+ T cells rather than CD3+CD8+. Importantly, mRNA analysis showed a distinct cytokine signature: while levels of IL12B, IL1A, IL6 and IL23 were similar between the two groups, the characteristic PSO‐associated cytokines IL8, IL17A, IL22, IL19 and IL36G were expressed at very low levels in CLP. In contrast, CLP lesional skin was dominated by the expression of IFNG, IL21, IL4, IL12A and TNF. Immunohistochemistry confirmed the dominance of IL‐21, IFN‐ɣ and also pSTAT1 in the dermal infiltrate of CLP, while IL‐17A was more present in PSO. Collectively, this study improves our understanding of the immunological factors dominating CLP. The dominating cytokines and signalling proteins identified suggest that anti‐cytokine therapeutics like JAK inhibitors may be beneficial in CLP.
Topics

No keywords indexed for this article. Browse by subject →

References
57
[6]
Immunology of Psoriasis

Michelle A. Lowes, Mayte Suárez-Fariñas, James G. Krueger

Annual Review of Immunology 10.1146/annurev-immunol-032713-120225
[11]
European S1 guidelines on the management of lichen planus: a cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology

D. Ioannides, E. Vakirlis, L. Kemeny et al.

Journal of the European Academy of Dermatology and... 10.1111/jdv.16464
[13]
IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus

Shuai Shao, Lam C. Tsoi, Mrinal K. Sarkar et al.

Science Translational Medicine 10.1126/scitranslmed.aav7561
[19]
Ismail FF "Clinical healing of erosive oral lichen planus with tildrakizumab implicates the interleukin‐23/interleukin‐17 pathway in the pathogenesis of lichen planus" Australas J Dermatol (2019)
[20]
Knisley RR "Lichen planus pemphigoides treated with ustekinumab" Cutis (2017)
[47]
Carbone T "CD56 highCD16 ‐ NK cell involvement in cutaneous lichen planus" Eur J Dermatol (2010)

Showing 50 of 57 references

Metrics
85
Citations
57
References
Details
Published
Nov 12, 2020
Vol/Issue
30(2)
Pages
262-270
License
View
Authors
Cite This Article
Katharina Pietschke, Julia Holstein, Katharina Meier, et al. (2020). The inflammation in cutaneous lichen planus is dominated by IFN‐ϒ and IL‐21—A basis for therapeutic JAK1 inhibition. Experimental Dermatology, 30(2), 262-270. https://doi.org/10.1111/exd.14226
Related

You May Also Like

The skin: an indispensable barrier

Ehrhardt Proksch, Johanna M. Brandner · 2008

1,587 citations

The 500 Dalton rule for the skin penetration of chemical compounds and drugs

Jan D. Bos, Marcus M. H. M. Meinardi · 2000

1,195 citations

Multimodal skin lesion classification using deep learning

Jordan Yap, William Yolland · 2018

268 citations